Charge
The charge of the Personalized Health Care Committee is to identify, prioritize, and coordinate issues related to the safe and effective delivery of personalized health care. The committee will monitor the testing landscape, make recommendations, and/or take action on behalf of the established councils and committees of the College of American Pathologists.
This committee reports to the Council on Scientific Affairs. View a list of the Current Committee Members and find additional resources in the Precision Medicine topic page.
Commitment
| Time Commitment Requirements | |
|---|---|
| Number of face-to-face meetings | 3 |
| Length of meetings | 1 to 1.5 days |
| Typical meeting days | Friday and Saturday |
| Meeting locations | TBD |
| Number of conference calls | 2 |
| Hours/year of committee work required outside of meetings | Members 36+, Chair 140+ |
| Additional travel or time commitments | Committee member attendance at the CAP annual meeting is strongly encouraged. |
Activities of Committee
The Personalized Health Care Committee will focus on coordination, monitoring, and communication facilitation as it relates to personalized health care and its impact on key activities of the College including:
- Government advocacy
- Patient advocacy
- Proficiency testing
- Resources for reporting of pathology results of tests that have personalized health care implications, such as risk stratification, therapy selection, etc.
- Education of pathologists regarding the concept and practice of personalized medicine and clinicals to understand pathology results as they pertain to personalized health care
Expertise or Experience
Committee members must have a working knowledge of the science of personalized health care along with one or more specific areas of expertise:
- Medical Genetics
- Molecular Medicine
- Pharmacogenomics
- Informatics
- Anatomic Pathology
- Clinical Pathology
- Biobanking
- Public Policy and Economic Affairs
- Continuing Medical Education
Benefits of Committee Membership
- Opportunity to highlight their unique contribution to clinical decision making and patient care
- Opportunity to guide pathologists’ evolution in becoming key consultants in the evaluation of individualized therapies based on genomic analyses, likely including recommendation for specific prescription drugs and further diagnostic testing when necessary